Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials

Journal article

Nicum S. and Blagden SP., (2022), Clinical cancer research

Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.

Journal article

Pantziarka P. and Blagden S., (2022), Cancers (basel), 14

Targeting MAPK in recurrent, low-grade serous ovarian cancer.

Journal article

Blagden SP., (2022), Lancet (london, england), 399, 499 - 501

Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer

Journal article

Kazmi F. et al, (2021), Cochrane database of systematic reviews, 2021